Allurion Receives Continuing Notification of NYSE Listing Standards Page 1

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the Company’s average market capitalization was less than $50.0 million for the consecutive 30 trading day period ended August 29, 2024 and the Company’s last reported net worth as of August 29, 2024 was less than $50.0 million. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE.

In accordance with NYSE procedures, the Company intends to file a plan with the NYSE within 45 days of receipt of the notice advising it of the final action(s) the Company has taken, is taking or intends to take to bring it into compliance with the NYSE’s continued listing standards. If the NYSE accepts the Company’s plan, the Company’s common stock will remain listed and traded on the NYSE during the 18-month restoration period, subject to the Company’s compliance with other NYSE continued listing standards and continued periodic review by the NYSE of the Company’s progress with respect to its plan.

The notification will not have an immediate impact on the listing of the Company’s common stock, which will remain listed and traded on the NYSE during the recovery period, subject to the Company’s compliance with other NYSE standards for continued listing. In addition, the notification is not expected to affect the Company’s ongoing business operations or reporting requirements with the U.S. Securities and Exchange Commission.

About Allurion
Allurion is committed to ending obesity. The Allurion Program is a weight loss platform featuring the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-free intragastric weight loss balloon, and provides access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers with the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available separately from the Allurion Program for healthcare providers to customize, monitor, and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical, or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.